Molecular pathology of prostate cancer: The key to identifying new biomarkers of disease

Endocrine-Related Cancer

Volumn 11, Issue 3, 2004, Pages 477-488

  Foley, Ruth ^a   Hollywood, Donal ^a   Lawler, Mark ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; COMPLEMENTARY DNA; HEPSIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER GROWTH; CELL CYCLE; DIAGNOSTIC VALUE; DISEASE MARKER; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; HUMAN; MOLECULAR BIOLOGY; POINT MUTATION; PROGNOSIS; PROSTATE CANCER; REVIEW; STEROID METABOLISM;

HUMANS; MALE; MOLECULAR BIOLOGY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 4944255650     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00699     Document Type: Review

References (87)

1. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R & Inuzuka M 1992 Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Research 52 5991-5996.
2. Bakin RE, Gioeli D, Sikes RA, Bissonette EA & Weber MJ 2003 Constitutive activation of the Ras/mitogen-activated protein kinase signalling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Research 63 1981-1989.
3. Baretton GB, Klenk U, Diebold J, Schmeller N & Lohrs U 1999 Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. British Journal of Cancer 80 546-555.
4. Beckett ML, Lipford GB, Haley CL, Schellhammer PF & Wright GL Jr 1991 Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Research 51 1326-1333.
5. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX & Olsson H 1999 CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. British Journal of Cancer 81 672-676.
6. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G & Kallioniemi OP 1999a Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Research 59 803-806.
7. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G & Kallioniemi OP 1999b Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. Journal of the National Cancer Institute 91 1758-1764.
8. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N & Isaacs WB 1999 DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research 59 5975-5979.
9. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS & Sidransky D 1997 Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Research 57 4997-5000.
10. Carter BS, Epstein JI & Isaacs WB 1990 ras gene mutations in human prostate cancer. Cancer Research 50 6830-6832.
11. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566.
12. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ & Brinkmann AO 1997 Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Research 57 4075-4081.
13. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM & Warner J 1994 Results of conservative management of clinically localized prostate cancer. New England Journal of Medicine 330 242-248.
14. Correa-Cerro L, Wohr G, Haussler J, Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P, Just W, Paiss T, Cantu JM & Vogel W 1999 (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. European Journal of Human Genetics 7 357-362.
15. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285.
16. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
17. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ & Bostwick DG 1997 Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49 857-862.
18. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA & Chinnaiyan AM 2001 Delineation of prognostic biomarkers in prostate cancer. Nature 412 822-826.
19. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT & Barrett JC 1995 KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268 884-886.
20. Edwards J, Krishna NS, Mukherjee R, Watters AD, Underwood MA & Bartlett JM 2001 Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU International 88 633-637.
21. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC & Isaacs WB 1995 Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Research 55 4813-4817.
22. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews Cancer 1 34-45.
23. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P & Navone NM 2002 The association of p21(WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clinical Cancer Research 8 775-781.
24. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG & Matusik RJ 1986 Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Research 46 1535-1538.
25. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa M, Sugimura Y & Kawamura J 2003 Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 56 319-325.
26. Gandini O, Luci L, Stigliano A, Lucera R, Di Silverio F, Toscano V & Cardillo MR 2003 Is DD3 a new prostate-specific gene? Anticancer Research 23 305-308.
27. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr & Weber MJ 1999 Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Research 59 279-284.
28. Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G & Culig Z 2002 Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clinical Cancer Research 8 2356-2361.
29. Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M & Miller K 2001 DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58 335-338.
30. Gotoh A, Shirakawa T, Wada Y, Fujisawa M, Okada H, Kamidono S & Hamada K 2003 The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells. BJU International 92 314-318.
31. Gumerlock PH, Poonamallee UR, Meyers FJ & deVere White RW 1991 Activated ras alleles in human carcinoma of the prostate are rare. Cancer Research 51 1632-1637.
32. Halvorsen OJ, Haukaas SA & Akslen LA 2003 Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research 9 1474-1479.
33. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA & Schalken JA 2003 DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. European Urology 44 8-16.
34. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW & Coetzee GA 1997 Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. Journal of the National Cancer Institute 89 166-170.
35. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M & Block N 2002 Her2 expression in prostatic cancer: a comparison with mammary carcinoma. Journal of Urology 168 1412-1414.
36. Kirby RS, Christmas TJ & Brawer MK 2001 Prostate Cancer, edn 2. London: Mosby.
37. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL & Vande Woude GF 2002 High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60 1113-1117.
38. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T & Kallioniemi OP 1997 Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Research 57 314-319.
39. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW & Schalken JA 2002 DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Research 62 2695-2698.
40. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, Dunn RL, Chinnaiyan AM & Rubin MA 2002 Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. American Journal of Pathology 161 841-848.
41. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W & Trapman J 1991 Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer 48 189-193.
42. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V & Gerald WL 2002 Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Research 62 4499-4506.
43. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC & Fisher PB 2003 Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22 8758-8773.
44. Leibovich BC, Cheng L, Weaver AL, Myers RP & Bostwick DG 2000 Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. Journal of Urology 163 1756-1760.
45. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM & Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Research 52 6940-6944.
46. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M & Sellers WR 1999 Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Research 59 4291-4296.
47. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE & Reichardt JK 1997 A prevalent missense substitution that modulates activity of prostatic steroid 5 alpha-reductase. Cancer Research 57 1020-1022.
48. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL & Lamb DJ 2000 Androgen receptor mutations in prostate cancer. Cancer Research 60 944-949.
49. Meid FH, Gygi CM, Leisinger HJ, Bosman FT & Benhattar J 2001 The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. Journal of Urology 165 1802-1805.
50. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD & deVere White RW 1998 Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83 2534-2539.
51. Nan B, Snabboon T, Unni E, X-J Yuan, Whang YE & Marcelli M 2003 The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. Journal of Molecular Endocrinology 31 169-183.
52. Nesslinger NJ, Shi XB & deVere White RW 2003 Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Research 63 2228-2233.
53. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP & Visakorpi T 2000 Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. Journal of Urology 164 1992-1995.
54. Parkin DM, Bray FI & Devesa SS 2001 Cancer burden in the year 2000. The global picture. European Journal of Cancer 37 S4-S66.
55. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC & Chung LW 1995 c-met proto-oncogene expression in benign and malignant human prostate tissues. Journal of Urology 154 293-298.
56. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ & Sutherland RL 2000 Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Research 60 1585-1594.
57. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS & Buttyan R 1995 Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Research 55 4438-4445.
58. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA & Day ML 2001 Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Research 61 489-492.
59. Rhodes DR, Barrette TR, Rubin MA, Ghosh D & Chinnaiyan AM 2002 Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Research 62 4427-4433.
60. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM & Rubin MA 2003 Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. Journal of the National Cancer Institute 95 661-668.
61. Roylance R, Spurr N & Sheer D 1997 The genetic analysis of prostate carcinoma. Seminars in Cancer Biology 8 37-44.
62. Sadar MD 1999 Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. Journal of Biological Chemistry 274 7777-7783.
63. Santos ML, Sarkis AS, Nishimoto IN & Nagai MA 2003 Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. Cancer Detection and Prevention 27 321-326.
64. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S & Dahiya R 2002 Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. Journal of the National Cancer Institute 94 384-390.
65. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ & Jenkins RB 1999 Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. Journal of the National Cancer Institute 91 1574-1580.
66. Savanainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ & Visakorpi T 2002 Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. American Journal of Pathology 160 339-345.
67. Schalken JA, Hessels D & Verhaegh G 2003 New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 62 S34-S43.
68. Shen R, Su ZZ, Olsson CA & Fisher PB 1995 Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. PNAS 92 6778-6782.
69. Silver DA, Pellicer I, Fair WR, Heston WD & Cordon-Cardo C 1997 Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research 3 81-85.
70. Small EJ & Roach M 3rd 2002 Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Seminars in Oncology 29 264-273.
71. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW & Srivastava S 2000 PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. PNAS 97 12216-12221.
72. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R & Zhang Z 2001 Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared with benign prostatic hyperplasia. Journal of Urology 166 2171-2177.
73. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA & Ostrander EA 1997 Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Research 57 1194-1198.
74. Stubbs AP, Abel PD, Golding M, Bhangal G, Wang Q, Waxman J, Stamp GW & Lalani EN 1999 Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. American Journal of Pathology 154 1335-1343.
75. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B & Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 59 2511-2515.
76. Tilley WD, Buchanan G, Hickey TE & Bentel JM 1996 Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research 2 277-285.
77. Ueda T, Bruchovsky N & Sadar MD 2002 Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. Journal of Biological Chemistry 277 7076-7085.
78. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA & Chinnaiyan AM 2002 The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 624-629.
79. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO & Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 173 534-540.
80. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J & Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 401-406.
81. Waghray A, Schober M, Feroze F, Yao F, Virgin J & Chen YQ 2001 Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Research 61 4283-4286.
82. Wallen MJ, Linja M, Kaartinen K, Schleutker J & Visakorpi T 1999 Androgen receptor gene mutations in hormone-refractory prostate cancer. Journal of Pathology 189 559-563.
83. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr & Hampton GM 2001 Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 61 5974-5978.
84. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, Soppett D & Srivastava S 2000a PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Research 60 6568-6572.
85. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KB, Badaro R & Reed SG 2000b Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Research 60 1677-1682.
86. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF & Chang C 1999 From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96 5458-5463.
87. Zhuang SH & Burnstein KL 1998 Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139 1197-1207.